AMAM — Ambrx Biopharma Income Statement
0.000.00%
- $1.76bn
- $1.54bn
- $7.40m
Annual income statement for Ambrx Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 10.3 | 13.7 | 7.46 | 7.4 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 32.8 | 26.8 | 71.9 | 83.8 |
Operating Profit | -22.5 | -13.1 | -64.4 | -76.4 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -22.3 | -17.8 | -68.3 | -76.1 |
Provision for Income Taxes | ||||
Net Income After Taxes | -22.3 | -17.8 | -68.3 | -78 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | -20.1 | -16.5 | -68.1 | -78 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -20.1 | -16.5 | -68.1 | -78 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.076 | -0.063 | -0.251 | -0.265 |